Stemirna Therapeutics Co., Ltd, an mRNA drug developer based in Shanghai, has obtained Emergency Use Authorization (EUA) in Laos for its in-house developed COVID-19 mRNA vaccine, used for people aged 18 and above to prevent COVID-19 pneumonia through active immunization. The product, the first home-grown COVID-19 mRNA vaccine approved in Laos, is the first COVID-19 variant mRNA vaccine obtaining EUA status in China. Stemirna has initiated a vaccine manufacturing base program in Laos, expected to produce 20 million jabs per year in the country.
Company Background and Technology Platform
Founded in 2016, Stemirna boasts of a proprietary mRNA whole industry chain technology platform, preparation structure LPP technology, cloud computing-based antigen analysis, prediction, and sequence optimization platform, and a complete mRNA vaccine analysis and quality control technology platform. The company’s mRNA delivery system is under patent protection in the US, Europe, Japan, and Hong Kong, among others.-Fineline Info & Tech
